Centivax
Accelerating the world's transition to a post-pathogen humanity.
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- centivax.com
- Total Funding
- $92.0M
- Last Round
- $37.0M Series BMar 2026
- Rounds
- 3
About
Centivax is a clinical-stage universal immunity company deploying a proprietary computational immune-engineering platform to develop broad-spectrum vaccines and therapeutic antibodies. Founded in 2019 by computational immunologist Jacob Glanville, the company's lead program is a universal influenza vaccine currently in Phase 1 clinical trials, which was awarded a Gates Foundation Grand Challenge. Centivax is also developing universal vaccines for other pathogens and antivenom therapies. The company is headquartered in South San Francisco, California and has raised over $55 million in funding.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Mar 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...